| Gene Therapy Net Newsletter |
|
|
| |
| |
News: Updates on gene therapy for ‘bubble boy’ disease and cellular immunotherapy at ASGCT
|
|
|
|
|
St. Jude Children’s Research Hospital scientists will discuss research on cellular therapies for pediatric cancer and more at the annual gathering of the professional society for gene and cellular therapy researchers.
Read more…
|
|
|
|
|
|
|
|
Conference: TCR-based Therapies for Solid Tumors Summit
|
|
|
|
|
Are you using TCRs to target solid tumors yet? With Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail, 2022 is fast becoming the year for TCRs.
Join the TCR-based Therapies for Solid Tumors Summit (June 27-29, 2022) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies.
Featuring 24+ expert speakers, this summit will address the toughest challenges in TCR development, such as improving TCR discovery and efficacy, combating the tumor microenvironment, optimizing target selection and advancing manufacturing, preclinical and clinical processes. Take a look at the full event guide to learn more.
Gene Therapy Net is also pleased to announce our exclusive discount code for your use. Save 10% on your pass to the summit with the code ‘GTN10’!
Register now…
|
|
|
|
|
|
|
|
Conference: 2nd Oligonucleotides for CNS Summit
|
|
|
|
|
Dedicated to providing you with the insights you need to create clinically defining oligonucleotide therapeutics, the 2nd Oligonucleotides for CNS Summit, June 13-15, 2022, will unite a multinational faculty of experts from Eli Lilly, Roche, Biogen, Alnylam, Servier, Stoke Therapeutics and more to divulge the critical insights you need to accelerate your oligonucleotide therapeutic development against Alzheimer’s, Huntington’s, Glioblastoma and more!
Register now…
|
|
|
|
|
|
|
|
Conference: 2nd Tumor Myeloid-Directed Therapies Summit
|
|
|
|
|
Returning in 2022, the 2nd Tumor Myeloid-Directed Therapeutics Summit, June 14 - 16, 2022, is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function.
Designed for experts working directly on myeloid-directed therapies and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment
Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more
With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.
Register now…
|
|
|
|
|
|
|
|
Conference: 1st Rare & Genetic Neurodegenerative Drug Development Summit
|
|
|
|
|
With multiple big pharma declaring prioritization of rare neurological disorders; sound-proofing translational decision making to bring disease-modifying therapies to genetically defined, neurodegenerative populations is both a powerful and highly challenging mission.
The inaugural Rare & Genetic Neurodegenerative Drug Development Summit (June 22- 23, 2022) is hosting enriched, cross-sponsor discussions to re-shape and guide strategic and translational decision-making targeting genetically defined populations. This modality-agnostic, translational focused event for R&D and early clinical heads provides the perfect opportunity to prioritize, assess, and realize small molecule, antibody or genetic therapy pipeline potential in rare neurological disorders more confidently.
Uniquely positioned to provide strategic insights across two days of exclusive content, join industry pioneers including Novartis, Sanofi, Merck, Servier, Triplet Therapeutics and many more as they troubleshoot key challenges, including overcoming heterogeneity within homogenous genetic groups dissecting whether phenotypes are a cause of consequence of disease, and identifying additional druggable opportunities from biological pathways to achieve greater therapeutic benefit.
Make sure to download the full event guide to explore the 2-day schedule.
Register now…
|
|
|
|
|
|
|
|
Conference: Cell Therapy at the Limits
|
|
|
|
|
‘Cell Therapy at the Limits’ takes place at the Royal College of Physicians in London on 27 & 28 June 2022. Healthcare professionals from across the UK, Europe and beyond will gather to discuss the very latest developments in Cell Therapy research and treatment, with presentations from a host of world class speakers. With a €200 flight cost contribution for non-UK delegates and complimentary 4* hotel accommodation close to the venue on the night of the 27 June it’s an event that no interested clinician or researcher should miss. Check the website for more details and to register whilst places are still available
Register now…
|
|
|
|
|
|
|
|
Conference: Onco Cell Therapy Summit (OCTS) USA
|
|
|
|
|
The 7th Onco Cell Therapy Summit (June 29-30, 2022, Boston) is the only conference that covers all cell therapy modalities; we take a holistic view to cover the developments and challenges across R&D, manufacturing and logistical operations. Leaders from biotech and academia will explore autologous and allogeneic (including iPSC-derived) T cell, NK cell and macrophage therapies – how they are developed, how they are produced, and how they are delivered to improve the outcomes of cancer patients. The agenda covers a full landscape of pioneering companies in the space, including Kita Pharma, Eureka, Tidal Therapeutics, Instil Bio, FDA, Bristol Myers Squibb, TC Biopharm, Aleta Biotherapeutics and many more.
Book a pass today and get 10% off using code ‘GeneTherapyNet10’.
Register now…
|
|
|
|
|
|
|
|
Conference: 3rd Annual Gene Therapy for Neurological Disorders Europe
|
|
|
|
|
Returning to Paris in 11–13 July, 2022 as its first in-person event, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.
Don’t miss your chance to join Europe’s only industry-focused event specifically dedicated to overcoming the niche challenges of targeting the CNS with gene therapy. Access NEW content such as sharing MHRA insights on regulatory challenges, addressing Europe’s payer considerations with the NHS, discussing specific European clinical trial nuances and hearing from Europe’s leading neurosurgeons at the forefront of gene therapy delivery and devices.
Register now…
|
|
|
|
|
|
|
|
Conference: BCMA-Targeted Therapies Summit
|
|
|
|
|
With the undeniable excitement in the BCMA field over the past few months, the BCMA-Targeted Therapies Summit, July 12-14, 2022, returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline.
Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond. Take a look at the full event guide to learn more.
Gene Therapy Net is also pleased to announce our exclusive discount code for your use. Save 10% on your pass to the summit with the code ‘GTN10’!
Register now…
|
|
|
|
|
|
|
|
Conference: iPSC Manufacturing Summit
|
|
|
|
|
With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy, the brand-new iPSC Manufacturing Summit, July 26-28, 2022, is the only summit dedicated to solving the manufacturing, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients.
This forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products, with in depth case studies aimed to develop optimal differentiation, cryopreservation, and analytical protocol to enhance process development to ensure it is robust, rapid and repeatable.
Our 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization, enhance iPSC product quality, and integrate successful gene-editing into your manufacturing. Take a look at the full event guide to learn more.
Gene Therapy Net is also pleased to announce our exclusive discount code for your use. Save 10% on your pass to the summit with the code ‘GTN10’!
Register now…
|
|
|
|
|
|
|
|
Upcoming conferences and meetings
|
|
|
|
- 16 - 19 May 2022 - American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting - Washington, D.C.
- 17 - 18 May 2022 - Advanced Therapies (ATMP) – Challenges for Routine Applications - Frankfurt am Main, Germany
- 24 - 26 May 2022 - 2nd Genetic Vaccine Development for Infectious Diseases Summit - Boston, MA
- 24 - 26 May 2022 - ALS Drug Development Summit - Gene & Cell Therapies - Boston, MA
- 24 - 26 May 2022 - Next Generation RNA Therapeutics Summit - Boston, MA
- 30 May - 1 June 2022 - 3rd Annual Gene Therapy Analytical Development Europe Summit 2022 - London, UK
- 7 - 9 June 2022 - 2nd Annual Gene Therapy Patient Engagement Summit - Boston, MA
- 13 - 15 June 2022 - 2nd Oligonucleotides for CNS Summit - Boston, MA
- 13 - 17 June 2022 - 9th Monolith Summer Symposium, mRNA, Vaccines, Gene Therapy Vectors - Portoroz, Slovenia
- 14 - 16 June 2022 - Next Generation CAR & T Cell Therapies 2022 event - San Francisco, CA
- 14 - 16 June 2022 - 2nd Tumor Myeloid-Directed Therapies Summit - Gene and Cell Therapies - Boston, MA
- 20 - 23 June 2022 - 2nd Inner Ear Disorders Therapeutics Summit - Gene Therapies - Boston, MA
- 22 - 23 June 2022 - Rare & Genetic Neurodegenerative Drug Development Summit - Gene Therapies - Boston, MA
- 27 - 28 June 2022 - Cell Therapy at the Limits - London, UK
- 27 - 29 June 2022 - 3rd TCR-based Therapies for Solid Tumors Summit - Boston, MA
- 29 - 30 June 2022 - Onco Cell Therapy Summit (OCTS) - Boston, MA
- 11 - 13 July 2022 - 3rd Annual Gene Therapy for Neurological Disorders Europe - Paris, France
- 11 - 13 July 2022 - World Orphan Drug Congress USA 2022 - Boston, MA
- 12 - 14 July 2022 - In Vivo Engineering of Therapeutic Cells Summit - Boston, MA
- 12 - 14 July 2022 - BCMA Targeted Therapies - CAR-modified T-cell therapy - Boston, MA
- 18 - 20 July 2022 - 2nd Annual Next Generation Gene Therapy Vectors Summit - Boston, MA
- 26 - 28 July 2022 - 3rd Gamma Delta T Therapies Summit - Boston, MA
- 26 - 28 July 2022 - 2nd Annual mRNA-Based Therapeutics Summit - Boston, MA
- 26 - 28 July 2022 - iPSC Manufacturing Summit - Gene and Cell therapies - Boston, MA
- 20 - 21 September 2022 - Cell & Gene Therapy USA 2022 - Online event
- 19 - 23 September 2022 - 7th Annual CAR-TCR Summit - Boston, MA
- 21 - 22 September 2022 - Oligonucleotide Therapeutics and Delivery 2022 - London, UK
- 26 - 28 September 2022 - International Human Gene Therapy Conference - Melbourne, Australia
- 11 – 14 October 2022 - XXIX Congress of the European Society of Gene and Cell Therapy (ESGCT) - Edinburgh, UK
|
|
|
|
|
|
|
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net, Ebola Virus Net, Chikungunya Virus Net, Zika Virus Net and Corona Virus Net.
|
|
|
|
|
|
This email was sent to This email address is being protected from spambots. You need JavaScript enabled to view it.
|
|
|
You've received this email because you've subscribed to our newsletter.
|
|
|
|
|
|
|
|
|
